Welcome to our dedicated page for Pacific Biosc SEC filings (Ticker: PACB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, annual and quarterly reports, and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on PacBio’s financial performance, risk factors, and business operations related to its advanced sequencing solutions and integrated genetic analysis platforms.
For a life science technology company like PacBio, investors often look to annual reports on Form 10-K and quarterly reports on Form 10-Q for discussions of revenue from instruments, consumables, and services, as well as commentary on product adoption, research collaborations, and regional trends. Current reports on Form 8-K, such as the November 5, 2025 filing that furnished a press release on third quarter 2025 financial results, provide timely updates on material events and earnings announcements.
Stock Titan enhances these SEC filings with AI-powered summaries designed to explain key sections in clear language. Instead of reading full-length documents unaided, users can rely on AI-generated highlights to understand topics such as PacBio’s use of GAAP and non-GAAP financial measures, its description of sequencing platforms and applications, and management’s discussion of business risks and opportunities.
In addition to periodic reports and 8-Ks, investors may also review proxy statements and, where applicable, insider transaction reports on Form 4 to understand equity-related activity by officers and directors. With real-time updates from EDGAR and AI-assisted insights, this PACB filings page helps users quickly locate and interpret the regulatory information that PacBio provides about its operations in genomic sequencing and analytical laboratory instruments.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer James R. Gibson II reported an open-market sale of 88,185 shares of common stock at a weighted average price of $1.37 per share. According to the filing, these shares were mandatorily sold to cover tax withholding obligations tied to vesting restricted stock units, and he continues to hold 1,245,663 shares directly.
Pacific Biosciences of California Inc: The Vanguard Group filed Amendment No. 4 to a Schedule 13G/A reporting 0 shares beneficially owned (0%) as of 03/13/2026. The filing notes an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries to report separately.
Pacific Biosciences of California, Inc. disclosed two developments. First, Chief Accounting Officer Michele Farmer will voluntarily resign effective March 21, 2026, to pursue another opportunity. The company states her departure is not related to any disagreement over operations or accounting, and she will not receive severance. Chief Financial Officer Jim R. Gibson will also serve as principal accounting officer, with no change to his compensation.
Second, on March 5, 2026, the company signed a binding term sheet with Personal Genomics of Taiwan, Inc. It provides a worldwide, royalty-free, non-exclusive license to U.S. Patent No. 7,767,441 and related patents, plus a five-and-a-half-year covenant not to sue under PGI patents, and dismissal of all litigation between the parties. Pacific Biosciences will make fixed payments of $8,000,000 in the first quarter of 2026 and $5,000,000 in the first quarter of each of 2027, 2028 and 2029, with the 2027 payment increasing by $1,000,000 if 2026 revenue reaches $165,000,000 and by another $1,000,000 if it reaches $180,000,000.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director Christopher Gibson reported equity awards connected to his election to the Board. On March 3, 2026, he received stock options for 73,087 shares at an exercise price of $0.00 and a grant of 53,913 shares of common stock represented by restricted stock units.
The RSUs vest in three equal annual installments on March 3, 2027, 2028, and 2029, conditioned on continued Board service. One‑third of the stock options vest on March 3, 2027, with the remaining options vesting in equal monthly installments over the following 24 months while he remains a director.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filed an initial ownership report for Christopher Gibson on Form 3. The filing identifies Gibson as a director of the company and does not list any buy, sell, or other share transactions. It simply establishes his status as an insider for future reporting.
Pacific Biosciences of California, Inc. appointed Christopher Gibson, Ph.D., to its Board of Directors as a Class I director effective March 3, 2026, expanding the board to ten members. His initial term runs until the 2026 annual meeting, and he will also serve on the Science and Technology Committee.
Dr. Gibson co-founded and chairs Recursion, a clinical-stage biotechnology company known for its AI-driven drug discovery platform that combines large-scale biological data with machine learning. PacBio highlights his background in integrating automation, high‑dimensional biology and artificial intelligence as directly relevant to its strategy of pairing HiFi long-read sequencing with advanced analytics.
The company states there are no related-party transactions or family relationships involving Dr. Gibson that require disclosure, and he will receive compensation under PacBio’s standard non‑employee director policy along with the company’s standard indemnification agreement. A press release dated March 5, 2026, further describes his appointment and PacBio’s view that AI-enabled data tools are increasingly important as sequencing datasets grow.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Christian O. Henry reported an open-market sale of 12,497 shares of common stock at a weighted average price of $1.514 per share, in transactions ranging from $1.49 to $1.56, to cover tax withholding on vested restricted stock units. After these tax-related sales, he directly held 3,581,813 shares of PACB common stock.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Mark Van Oene reported an open-market sale of 6,504 shares of common stock at a weighted average price of $1.514 per share. The shares were mandatorily sold to cover tax withholding obligations from vesting restricted stock units, leaving him with 2,243,634 shares held directly.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Michele Farmer reported an automatic sale of common stock tied to tax withholding. On this Form 4, 2,979 shares were mandatorily sold to cover tax obligations from vesting restricted stock units at a weighted average price of $1.514 per share. After this tax-related transaction, Farmer directly held 305,948 shares of PACB common stock.